argenx Doubles Down on Immunology: Forte Deal Adds FB102 Optionality While VYVGART Momentum Funds the Next Growth Wave

Research evidence excerpt

argenx Doubles Down on Immunology: Forte Deal Adds FB102 Optionality While VYVGART Momentum Funds the Next Growth Wave

y, which is available at www.morganstanley.com/institutional/research/conflictpolicies. A

Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

As of June 30, 2026, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: 4D Molecular

Therapeutics Inc, Abivax, Alnylam Pharmaceuticals Inc, Amgen Inc., Arcutis Biotherapeutics, Inc., argenx SE, Arvinas Inc, Ascendis Pharma A/S, Atea Pharmaceuticals Inc, Axsome Therapeutics,

Belite Bio Inc, BeOne Medicines, Bicycle Therapeutics Plc, Biogen Inc, BridgeBio Pharma Inc, CG Oncology, Compass Pathways PLC, Crinetics Pharmaceuticals, CRISPR Therapeutics AG, Cullinan

Therapeutics, Cytokinetics Inc, Evommune Inc, Exelixis Inc., Genmab A/S, Gilead Sciences Inc., Halozyme Therapeutics, Inc, Incyte Corp, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, Kyverna

Therapeutics, Lakefront Biotherapeutics, Legend Biotech Corp, Mirum Pharmaceuticals, Moderna Inc, Neurocrine Biosciences Inc, Nurix Therapeutics Inc., ProKidney Corp, PTC Therapeutics,

Regeneron Pharmaceuticals Inc., Regenxbio Inc, Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, Sarepta Therapeutics Inc, Schrodinger Inc., Silence Therapeutics Plc, Structure

Therapeutics Inc, Ultragenyx Pharmaceutical Inc, United Therapeutics Corp, Vertex Pharmaceuticals, Viking Therapeutics Inc, Vir Biotechnology Inc.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Abivax, ABSCI CORP, AgomAb Therapeutics NV, Alnylam Pharmaceuticals